^
    22h
    RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC (clinicaltrials.gov)
    P2, N=5, Terminated, Replimune Inc. | Trial completion date: Mar 2027 --> Aug 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2027 --> Aug 2025; Business reasons.
    Trial completion date • Trial termination • Trial primary completion date • Mismatch repair • pMMR
    |
    EGFR (Epidermal growth factor receptor)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • RP3 • sturlimogene erparepvec (RP2)
    3d
    An Open-label, Single-arm, Exploratory Clinical Study to Evaluate the Efficacy and Safety of mecapegfilgrastim in Preventing Chemotherapy-Induced Neutropenia in Patients with Breast Cancer (ChiCTR2600116027)
    P2, N=48, Not yet recruiting, Beijing Cancer Hospital; Beijing Cancer Hospital
    New P2 trial
    |
    HHPG-19K (mecapegfilgrastim)
    6d
    Safety and Efficacy of Cyclophosphamide With Dual Mecapegfilgrastim and On-Demand Plerixafor for Salvage Mobilization in Patients With Initial Mobilization Failure: A Retrospective Cohort. (PubMed, J Clin Apher)
    In conclusion, CTX + PEG-rhG-CSF + on-demand PXF is a highly effective salvage mobilization strategy for patients with initial HSC mobilization failure, yielding higher CD34+ cell counts with fewer aphereses and acceptable safety. With balanced advantages in efficacy, safety, and cost-effectiveness, the CTX + PEG-rhG-CSF + on-demand PXF regimen can be a preferred salvage option for ASCT candidates with prior mobilization failure.
    Retrospective data • Journal
    |
    CD34 (CD34 molecule)
    |
    cyclophosphamide • HHPG-19K (mecapegfilgrastim) • plerixafor
    21d
    RPx: A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Replimune Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    RP3 • Tudriqev (vusolimogene oderparepvec-wtpg) • sturlimogene erparepvec (RP2)
    21d
    Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, Abramson Cancer Center at Penn Medicine | Initiation date: Nov 2025 --> Apr 2026
    Trial initiation date
    |
    docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • sturlimogene erparepvec (RP2)
    28d
    BRIA-ABC: Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. (clinicaltrials.gov)
    P3, N=404, Recruiting, BriaCell Therapeutics Corporation | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jan 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    carboplatin • capecitabine • cyclophosphamide • Halaven (eribulin mesylate) • Zynyz (retifanlimab-dlwr) • Bria-IMT (SV-BR-1-GM)
    1m
    Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT) (clinicaltrials.gov)
    P2, N=17, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial primary completion date: Nov 2025 --> Nov 2026 | Trial completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    plinabulin (BPI 2358) • Neulasta (pegfilgrastim)
    2ms
    Development and validation of a cell-based methodology to evaluate filgrastim relative affinity to granulocyte colony-stimulating factor receptor. (PubMed, J Immunoassay Immunochem)
    After performing a validation exercise, the method proved to be accurate, specific, and linear within an affinity interval of 75 to 130%; precise with a confidence interval of 93.6 to 114.2% and a coefficient of variation of 12.6%. The validation exercise proved that the proposed cell-based method is a viable alternative to evaluate the biological activity of filgrastim via the affinity for its receptor and it is suitable to be included as part of its biological characterization exercises as well as in comparability exercises for products coming from distinct manufacturing processes.
    Journal
    |
    CSF3R (Colony Stimulating Factor 3 Receptor)
    |
    Neupogen (filgrastim)
    2ms
    RMS13: Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy (clinicaltrials.gov)
    P2, N=115, Active, not recruiting, St. Jude Children's Research Hospital | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    Avastin (bevacizumab) • sorafenib • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • irinotecan • vincristine • dactinomycin • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • dexrazoxane
    2ms
    Efficacy and Safety of Pegfilgrastim in Patients With Severe Congenital Neutropenia. (PubMed, EJHaem)
    Larger studies are warranted to evaluate its long-term safety and efficacy. This trial is registered at https://irct.behdasht.gov.ir/ in Iranian Registry of Clinical Trials (IRCT) # IRCT20150125020786N3.
    Journal
    |
    RUNX1 (RUNX Family Transcription Factor 1) • CSF3R (Colony Stimulating Factor 3 Receptor)
    |
    Neulasta (pegfilgrastim)
    2ms
    BREASTIMMU02: Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, Centre Leon Berard | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • paclitaxel • Neulasta (pegfilgrastim)
    2ms
    BREASTIMMU02: Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer (clinicaltrials.gov)
    P2, N=90, Recruiting, Centre Leon Berard | Trial completion date: Sep 2025 --> Sep 2027 | Trial primary completion date: Jan 2025 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • paclitaxel • Neulasta (pegfilgrastim)